EP Patent

EP1181935B1 — Use of Olanzapine for the treatment of mental disorders resulting from cerebrovascular disorders

Assigned to Sumitomo Pharma Co Ltd · Expires 2005-09-21 · 21y expired

What this patent protects

The present invention provides an agent for treating mental disorders resulting from cerebrovascular disorder. Olanzapine, a compound which can block both serotonin-2 and dopamine-2 receptors is useful as a therapeutic agent therefor.

USPTO Abstract

The present invention provides an agent for treating mental disorders resulting from cerebrovascular disorder. Olanzapine, a compound which can block both serotonin-2 and dopamine-2 receptors is useful as a therapeutic agent therefor.

Drugs covered by this patent

Patent Metadata

Patent number
EP1181935B1
Jurisdiction
EP
Classification
—
Expires
2005-09-21
Drug substance claim
No
Drug product claim
No
Assignee
Sumitomo Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.